Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
about
Structural Diversity in the Type IV Pili of Multidrug-resistant AcinetobacterInsights on the Horizontal Gene Transfer of Carbapenemase Determinants in the Opportunistic Pathogen Acinetobacter baumanniiBiology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment OptionsAnticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter InfectionsAssociation of blaOXA-23 and bap with the persistence of Acinetobacter baumannii within a major healthcare system.In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.Fluorescence High-Throughput Screening for Inhibitors of TonB Action.Comparative Genomics of Two ST 195 Carbapenem-Resistant Acinetobacter baumannii with Different Susceptibility to Polymyxin Revealed Underlying Resistance Mechanism.Isolation and Characterization of Acinetobacter baumannii Recovered from Campylobacter Selective Medium.Occurrence of Diverse AbGRI1-Type Genomic Islands in Acinetobacter baumannii Global Clone 2 Isolates from South Korea.Acinetobacter baumannii Lipopolysaccharide Influences Adipokine Expression in 3T3-L1 Adipocytes.Global Gene Expression Profile of Acinetobacter baumannii During Bacteremia.Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.Clinical and molecular epidemiology of Acinetobacter baumannii bloodstream infections in an endemic setting.New molecules and adjuvants in the treatment of infections by Acinetobacter baumannii.Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.Evaluation of the synergistic effect of a combination of colistin and tigecycline against multidrug-resistant Acinetobacterbaumannii.Adaptation to Potassium-Limitation Is Essential for Acinetobacter baumannii Pneumonia Pathogenesis.Comparison of Minocycline Susceptibility Testing Methods for Carbapenem-Resistant Acinetobacter baumannii.Whole-Genome Sequencing Elucidates Epidemiology of Nosocomial Clusters of Acinetobacter baumannii.A Review of the Combination Therapy of Low Frequency Ultrasound with Antibiotics.Detection of antibiotic resistant Acinetobacter baumannii in various hospital environments: potential sources for transmission of Acinetobacter infections.Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials.Acinetobacter spp. Infections in Malaysia: A Review of Antimicrobial Resistance Trends, Mechanisms and Epidemiology.Effect of Incubation Temperature on Antibiotic Resistance and Virulence Factors of Acinetobacter baumannii ATCC 17978.High Proportions of Multidrug-Resistant Acinetobacter spp. Isolates in a District in Western India: A Four-Year Antibiotic Susceptibility Study of Clinical Isolates.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Molecular Epidemiology of Emerging blaOXA-23-like and blaOXA-24-like -Carrying Acinetobacter baumannii in Taiwan.Editorial commentary: the new Acinetobacter equation: hypervirulence plus antibiotic resistance equals big trouble.Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland.Characterization of Two Novel Bacteriophages Infecting Multidrug-Resistant (MDR) Acinetobacter baumannii and Evaluation of Their Therapeutic Efficacy in Vivo.Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea.RCH51, a multiply antibiotic-resistant Acinetobacter baumannii ST103IP isolate, carries resistance genes in three plasmids, including a novel potentially conjugative plasmid carrying oxa235 in transposon Tn6252.Use of adjuvants in the treatment of Acinetobacter baumannii.Distribution of virulence-associated genes and antimicrobial susceptibility in clinical Acinetobacter baumannii isolates.Association of virulence gene expression with colistin-resistance in Acinetobacter baumannii: analysis of genotype, antimicrobial susceptibility, and biofilm formation.
P2860
Q27728070-9480A212-97DD-41B5-AAE9-7BE127F4E0B6Q28078376-4F8F212A-D69D-48DA-B037-11ECC231A510Q30235064-8014D678-61DE-4A43-8911-394BCC3A00F7Q33732524-89E6D267-304F-46F7-972F-A52210DBD426Q35170448-DF560237-680D-424F-9612-D6FD2DE3F382Q36064268-8AB640FF-44BB-44E6-B4D1-30C9864E5D66Q36290577-B9C3C7B8-281D-4F58-845E-0397F670E7ADQ36292479-E0711988-155B-432B-913B-B2773B60EA5AQ36427137-5CBB85D6-AEEA-44C0-8C62-E144181FC6FAQ37421156-FE3BEBE7-5559-49DE-9C2E-25A25116B1FAQ37613048-505E3461-6973-4CF7-A69A-66F89861149DQ38696093-988D1759-5FB7-43C8-B4F9-2F0652C774C6Q38735255-D3E803D1-E5A8-425A-B2DD-74F80061B5DDQ38738509-63B17550-4EDF-4143-8C0A-7F50E9553FA1Q38746707-7E46B999-BA80-4133-92BF-70A2920D28B7Q38805100-2B85988B-EF72-43CB-AC8A-5A195B0AF261Q39167693-95DC1265-624E-48DD-9BA8-95A67EAD1901Q39218893-E70F0BE5-99C7-4300-AB84-628EC30CCE7DQ39613942-D1ABAB1C-14DE-40EF-94D8-17517D954146Q40112398-DED04679-9215-439F-8198-05E183E480ACQ40206558-748B21CA-3862-435D-989E-29BB1AB0248DQ40421190-25FD3271-FD7E-4517-91A1-84C9471C18A9Q40540026-CB0BC00F-C228-4A98-BBE9-3F8613E48D2DQ40630951-EA65F06B-15AD-438A-B5E4-4BD08FA9BD85Q45788097-9BEF52C5-7245-446E-A1F5-B069D41ACD61Q45796678-F7A4A141-A892-4D8C-8282-913CD8683AA4Q47129511-641D089A-A4F7-49F2-90CA-42A9D6CACA8FQ47194278-E5F1DB29-09BC-491A-A757-3FFDD69DA7BCQ47614131-756F7363-08DD-4AA0-976D-7838337B3D05Q47652694-25224815-4E6F-4D46-951E-2DA9E260F230Q47661746-FED87904-4828-48B3-8F6C-5BE28C4CC7C9Q50134172-D744E2B1-F368-4D90-B0B0-29BC14544EFEQ50940139-558DB9F6-23F1-4C59-A6CA-9B78FC2F7374Q52333196-22887940-E882-4BD2-9947-F8E338059FAAQ53683184-D0DB5C5B-6A02-4990-9FBB-716A8E106EF2Q53704499-0E6798FD-B842-4E35-BABA-6A63EB1BCD7FQ53746525-6E39374D-F30D-4E34-974D-C42E9F858FF6Q53806892-A2109D6A-3A7A-4F64-9FD2-109F853F1441Q54207272-C5268665-A89C-43DD-8828-84A7A2528146Q55135895-9955413E-511F-4A37-B4F9-BEC711B8C513
P2860
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@ast
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@en
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@nl
type
label
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@ast
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@en
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@nl
prefLabel
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@ast
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@en
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@nl
P2860
P50
P921
P3181
P356
P1476
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options
@en
P2093
Gerald Murray
P2860
P3181
P356
10.1055/S-0034-1398388
P407
P577
2015-02-02T00:00:00Z